TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06282575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanidatamab
Description: Administered intravenously (IV)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Administered intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered intravenously (IV)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Administered intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered intravenously (IV)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Administered intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered intravenously (IV)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Administered intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Administered intravenously (IV)
Study: NCT05643560

Intervention type: DRUG
Intervention: Damoctocog alfa pegol (Jivi, BAY94-9027)
Description: Intervention is given as part of routine medical practice.
Study: NCT06112418

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Cleerly CAD Staging System
Description: The Cleerly CAD Staging System is software that utilizes a proprietary algorithm to identify CAD, stage the severity of CAD when present, and generate a prognostic risk score to inform treatment decisions that support CV disease prevention.
Study: NCT06402006

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PENG block
Description: pericapsular nerve group block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LFCN block
Description: Lateral femoral cutaneous nerve block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESP block
Description: Erector spinae plane block
Study: NCT06502691

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive of standard care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive of standard care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy of Breast
Description: Undergo breast biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy of Breast
Description: Undergo breast biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo FDG PET/CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo FDG PET/CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Given FDG

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fludeoxyglucose F-18
Description: Given FDG

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fluorine F 18 Fluorthanatrace
Description: Given IV

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Fluorine F 18 Fluorthanatrace
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune Checkpoint Inhibitor
Description: Receive ICI treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immune Checkpoint Inhibitor
Description: Receive ICI treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly (ADP-Ribose) Polymerase Inhibitor
Description: Receive PARP inhibitor treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Poly (ADP-Ribose) Polymerase Inhibitor
Description: Receive PARP inhibitor treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo \[18F\]FTT PET

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo \[18F\]FTT PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FDG PET/CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo FDG PET/CT
Study: NCT04833010

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary Exercise Test
Description: Participants will complete a Cardiopulmonary Exercise test on cycle ergometer in which they will perform progressive step-exercise cycling to exhaustion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiopulmonary Exercise Test
Description: Participants will complete a Cardiopulmonary Exercise test on cycle ergometer in which they will perform progressive step-exercise cycling to exhaustion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Performance Test
Description: Cognitive Performance will be tested using a cognition application on an iPad during the Cardiopulmonary Exercise Test.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Performance Test
Description: Cognitive Performance will be tested using a cognition application on an iPad during the Cardiopulmonary Exercise Test.
Study: NCT06373731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elamipretide
Description: Subjects will receive once daily SC doses of 40 mg elamipretide for 96 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive once daily SC doses of Placebo 96 weeks
Study: NCT04672655

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ONBOARD
Description: Session 1: Overview; Wearing diabetes devices; Session 2: Managing CGM data; Session 3: CGM \& social situations; Session 4: Building trust with your CGM
Study: NCT06566443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Honokiol
Description: Honokiol will be given orally at a starting dose of 1 capsule (250 mg/ capsule) per day for 2 weeks. Dose levels will escalate based on dose-limiting toxicity occurrence. We will start at one capsule (250 mg) once daily, dose 0 would be one capsule (250 mg) twice daily, dose +1 would be 500mg in the AM and 250mg in the evening, and +2 would be 500 mg twice daily.
Study: NCT06387472

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI algorithm to evaluate photographs of skin test patch regions
Description: Interpretation of skin test patch regions via artificial intelligence (AI)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Allergen Patch
Description: Contains dime-sized disks which have different substance to which a person may be allergic.
Study: NCT05342701

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Skills Intervention
Description: The behavioral motor skill intervention (CHAMP) is an intervention strategy that uniquely address differences in children's development. CHAMP does not equate to a one size fits all approach. Children will be in an environment that promotes opportunities for them to development improvement in motor skills based on their specific individual needs and choices. The CHAMP intervention promotes a mastery climate that allows each individual child to be successful and learn while promoting intrinsic motivation and autonomy. CHAMP consists of 35 minutes/day X 3-4 days/week for 19 weeks (dose of 1995 - 2240 minutes). Each session will consist of three parts: (a) 3-5 min of motor skill introductory activity, (b) 25 min of motor skill instruction and practice, and (c) 3-5 min motor skill closure activity.
Study: NCT05232838

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eShunt Implant
Description: The eShunt System is intended to shunt cerebrospinal fluid from the intracranial subarachnoid space to the venous system for the treatment of patients with normal pressure hydrocephalus, reducing disability due to symptoms including one or more of gait disturbance, cognitive dysfunction and urinary incontinence.
Study: NCT05104515

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OVM-200
Description: The first part (Phase 1a) comprises a first-in-human (FIH) multiple-dose, sequential-cohort 3+3 design to establish a dose of OVM-200 that is safe and tolerable, and that elicits an immune response in humans.~This dose will be taken forward into the second part (Phase 1b) of the study. Phase 1b will further assess the safety and tolerability of the selected dose and investigate the immune and tumour response in 3 expansion cohorts of additional patients with NSCLC, ovarian cancer, and prostate cancer.
Study: NCT06525532

Intervention type: OTHER
Intervention: follow up
Description: performing a 3 Tesla MRI of the operated foot
Study: NCT05432791

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pazopanib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trabectedin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transthoracic Echocardiography
Description: Undergo TTE

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transthoracic Echocardiography
Description: Undergo TTE
Study: NCT06309784

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Drill Guidance System (DGS)
Description: During a standard surgical procedure where a drill/k wire is being inserted the surgeon may choose (in advance) to supplement their drilling with use of the Drill Guidance System. This will be a supplement to normal practice. it is anticipated it will make surgery more accurate, swifter and safer. If however the surgeon is not finding the DGS useful it can be abandoned and standard drilling with X-ray guidance used
Study: NCT04708834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Troriluzole (BHV-4157)
Description: 200 mg daily first 2 weeks, 280 daily following first 2 weeks
Study: NCT04091386

Intervention type: DRUG
Intervention: Damoctocog alfa pegol (Jivi, BAY94-9027)
Description: Intervention is given as part of routine medical practice
Study: NCT06210958

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intertransverse process block
Description: The patients will be randomized into 2 groups which will receive the different techniques of the intertransverse process block

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intertransverse process block
Description: The patients will be randomized into 2 groups which will receive the different techniques of the intertransverse process block
Study: NCT05692180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Benralizumab active solution will be administered SC to the patients.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution will be administered SC to the patients.
Study: NCT06253221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavacamten
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT04859283

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Intranasal dexmedetomidine 1µg/kg will be administered 30min before the induction of anesthesia using a LMA MAD Nasal-device

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intranasal saline (10 µL/kg) will be administered 30 min before the induction of anesthesia using a LMA MAD NasalTM -device. The dose is euvolemic to 1 µg/mL dexmedetomidine.
Study: NCT06108596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab with Interleukin-2+CAPOX
Description: Sintilimab with Interleukin-2+CAPOX
Study: NCT05534802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulinastatin
Description: On the basis of conventional treatment, according to the instructions or previous research doses (general anesthesia and tracheal intubation, after cardiopulmonary bypass transfer starts): 10,000 U/kg Ulinastatin (National Medicine Approval No. H19990134, Guangdong Tianpu Biochemical Pharmaceutical Co., Ltd. Co., Ltd., Guangzhou, China) was dissolved in 50 ml of normal saline for 1 hour and pumped through the central vein.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: saline
Description: On the basis of conventional treatment, 50 ml of normal saline for 1 hour and pumped through the central vein.
Study: NCT05457738

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-REVA® app
Description: Use of a smartphone app designed for home-based exercise therapy of patients with intermittent claudication. App's name is E-REVA®.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No E-REVA® app
Description: No use smartphone
Study: NCT04867954

Intervention type: OTHER
Intervention: Ensure Plus®
Description: In-between two MRI exams, patients will ingest a standardized meal of two cans (16oz) of Ensure Plus® (Abbott Laboratories), providing a 700cal meal (13g protein, 11g fat, 50g carbohydrates), proven to elicit a strong hyperemic splanchnic response.

Intervention type: OTHER
Intervention: Pre-clinical validation contrast enhanced MRI
Description: Participants will be asked to complete a single research visit that will include a contrast enhanced MRI scan lasting up to 1 hour. Participants will be asked to fast for at least 5 hours prior to the exam. Participants will be screened a final time for contraindications to contrast enhanced MR imaging; an IV will be placed; and participants will be positioned in the MR scanner, asked to lie as still as possible and to follow some breath hold instructions.

Intervention type: OTHER
Intervention: Pre-clinical validation contrast enhanced MRI
Description: Participants will be asked to complete a single research visit that will include a contrast enhanced MRI scan lasting up to 1 hour. Participants will be asked to fast for at least 5 hours prior to the exam. Participants will be screened a final time for contraindications to contrast enhanced MR imaging; an IV will be placed; and participants will be positioned in the MR scanner, asked to lie as still as possible and to follow some breath hold instructions.
Study: NCT05637281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indometacin
Description: Besides the conventional treatment, indomethacin will be given to the patients in the convention + indomethacin group.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: conventional treatment
Description: All enrolled patients received conventional management according to AP guidelines of International Association of Pancreatology and the Chinese Society of Gastroenterology, including goal-directed fluid resuscitation, oxygen supply even mechanical ventilation, and nutritional support if necessary.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional treatment
Description: All enrolled patients received conventional management according to AP guidelines of International Association of Pancreatology and the Chinese Society of Gastroenterology, including goal-directed fluid resuscitation, oxygen supply even mechanical ventilation, and nutritional support if necessary.
Study: NCT05128409

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XKH001 Injection
Description: 0.5mg/kg: 3Subjects,1Sentinel Participants 1.67mg/kg: 6Subjects, ,1Sentinel Participants 3.34mg/kg: 6Subjects,1Sentinel Participants 5.0mg/kg: 6Subjects, ,1Sentinel Participants 10.0mg/kg: 6Subjects,1Sentinel Participants

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: XKH001Placebo Injection
Description: 1.67mg/kg: 2Subjects,1Sentinel Participants 3.34mg/kg: 2Subjects,1Sentinel Participants 5.0mg/kg: 2Subjects,1Sentinel Participants 10.0mg/kg: 2Subjects, 1Sentinel Participants
Study: NCT04867954

Intervention type: OTHER
Intervention: Pre-clinical validation contrast enhanced MRI
Description: Participants will be asked to complete a single research visit that will include a contrast enhanced MRI scan lasting up to 1 hour. Participants will be asked to fast for at least 5 hours prior to the exam. Participants will be screened a final time for contraindications to contrast enhanced MR imaging; an IV will be placed; and participants will be positioned in the MR scanner, asked to lie as still as possible and to follow some breath hold instructions.

Intervention type: OTHER
Intervention: Clinical validation MRI
Description: Participants will be screened for any previous reactions to Ferumoxytol or GBCAs and dosing will be consistent with standard of care.~Participants will then undergo a research MRI lasting approximately 1.5 hours.~* All participants will be positioned in the MRI scanner for the initial scanning session (30 min) during which a 1/2 or 3/4 of the full dose of gadolinium based contrast agent (GBCA) or the total dose of Ferumoxytol will be administered.~* The first 50 participants will be removed from the scanner bore, repositioned, and scanned for an additional 15 minutes (repeatability testing).~* All participants will then be removed from the scanner and asked to consume 16 ounces of Ensure Plus®. After 20 minutes, they will be repositioned in the scanner for an additional scanning session (15 minutes) during which, the remaining 1/4 or 1/2 dose of GBCA will be administered, if required.

Intervention type: OTHER
Intervention: Pre-clinical validation contrast enhanced MRI + fasting
Description: Participants will be asked to complete a single research visit that will include a contrast enhanced MRI scan lasting up to 1.5 hours. Participants will be asked to fast for at least 5 hours prior to the exam. Participants will be screened a final time for contraindications to contrast enhanced MR imaging; an IV will be placed; and participants will be positioned in the MR scanner, asked to lie as still as possible and to follow some breath hold instructions.
Study: NCT06116682

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Given amivantamab-SC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT05419479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZIMBERELIMAB
Description: Via IV on two days per cycle, dosage per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZIMBERELIMAB
Description: Via IV on two days per cycle, dosage per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZIMBERELIMAB
Description: Via IV on two days per cycle, dosage per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOMVANALIMAB
Description: Via IV on two days per cycle, dosage per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOMVANALIMAB
Description: Via IV on two days per cycle, dosage per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOMVANALIMAB
Description: Via IV on two days per cycle, dosage per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX005M
Description: Via IV on two days per cycle, dosage per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX005M
Description: Via IV on two days per cycle, dosage per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX005M
Description: Via IV on two days per cycle, dosage per protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI
Description: every two weeks through an infusion at a dose determined by physician
Study: NCT05006599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin (Humulin® R U-100)
Description: Participants will administer 40 IU of Humulin® U-100 insulin four times per day with an intranasal delivery device.
Study: NCT06378138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-248
Description: Eligible patients will receive ICP-248 orally as per the protocol，once daily for every 28 days as one treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib
Description: Eligible patients will receive Orelabrutinib orally as per the protocol，once daily for every 28 days as one treatment cycle
Study: NCT04928846

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Telisotuzumab Vedotin
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: IV Infusion
Study: NCT05069077

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: In the music group, music that chosen by the participant will be played through a speaker by the nursing staff during outpatient hysteroscopy. Music will be played through a speaker instead of headphones in order to maintain good communication and interaction between the participant and the doctor.

Intervention type: OTHER
Group type: OTHER
Intervention: No music
Description: Participants in the non-music group will undergo outpatient hysteroscopy in the same setting and standard procedure without listening to any music.
Study: NCT05090371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: 3 loading doses followed by administration every 4 weeks as per label

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Disease modifying treatment (DMT)
Description: Other DMT with approved label use for treatment which participants were on at least 6 months prior to Screening